He will kill his work, his team and the science level made in Tucuman, Florencia González Lizárraga He is grateful for his acclaim from the British Historical Society of Argentina, most important country in the country. He won the Jorge Ponce Hornos Award after being selected among 350 work of scientists from across the country. "This is a job as a doctoral dissertation (she will become a biologist in Biological Sciences) I am the first author of the work, but we are doing it; Talk about these issues as a team, "she says. illuminating.
Florence was studied in the Molecular and Cellular Medical Institutions (Immca) Institute, which is the responsibility of the UNT, the Conicet and the Ministry of Health of the province, which is dependent on Rosana Chehín. The work is also counted on its collaboration at the UBA Advanced Microscopy Center which, guide His Pietrasanta. Yesterday was Flora when he spoke to the phone with LA GACETA.
The foundation of the study of the young antibiotic expert called dioxycycline, which belongs to the tetracyclines group. This antibiotic is capable of interacting with the Alpha-synuclein protein, which is responsible for the death of durcainérgicas neurons (those who communicate with other neurons through dopamine). These are the neurons that die in the people affected by Parkinson's disease.
However, doxycycline is not suitable for long-term diseases such as neurodegenerative diseases because it can have bacteria affecting.
"The second part of the work is that he has cure COL 3, which is also a tetracycline, but has been altered to prevent antibiotic activity to prevent it. And has an anti-inflammatory action and he will make an alpha-synuclein protein non-toxic. Therefore, dopano-niurons do not exist.
"In this way, Parkinson's disease stops. That is, it's not a curious medicine, as is the current treatment", and # 39; emphasizing Florence.
Indeed, the research is still in the level of a laboratory. In vitro and in vivo tests are being done, but there is still a long way for a degree of clinical trials in humans. Despite this, it's definitely not a big hope.
The second mention of the Ponce Hornos Prize was also for Tucuman: Luciana Medina, to work on Alzheimer's disease.